The Advertising Standards Authority (ASA) rated 43% of the research peptide ads it assessed as high compliance risk, according to its Pulse Report dated 1 October 2026. Aesthetics Journal covered the findings on 2 November.

How did the ASA study research peptide ads?

It captured four weeks of paid ads on Meta, Google, TikTok and website display, found 309,000 healthcare ads and picked seven topics for a closer look. The research peptide group held 1,240 ads. In the rated sample 0% were low risk, 57% medium and 43% high. The ASA says the work was "not intended to make formal compliance determinations", so these are risk ratings, not rulings.

What did it say about "research use only"?

The ASA says unauthorised research peptides intended for research rather than consumer use. Many ads looked like laboratory supply on the surface. Others implied consumer use through small order quantities, WhatsApp ordering, discounts, home delivery and discreet shipping. "Research use only" wording could conflict with the surrounding presentation and purchasing process.

What should UK readers take from it?

Judge a supplier by its whole presentation, not its disclaimer. Batch-specific COAs and plain laboratory language count for more than a footer. The ASA also flagged coded terms such as "chili peppers" in ads.

Scope for European readers

This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.